200 related articles for article (PubMed ID: 12871782)
1. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A
Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782
[TBL] [Abstract][Full Text] [Related]
2. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
3. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.
Senter PD; Beam KS; Mixan B; Wahl AF
Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
Wu MH; Yan B; Humerickhouse R; Dolan ME
Clin Cancer Res; 2002 Aug; 8(8):2696-700. PubMed ID: 12171903
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse R; Lohrbach K; Li L; Bosron WF; Dolan ME
Cancer Res; 2000 Mar; 60(5):1189-92. PubMed ID: 10728672
[TBL] [Abstract][Full Text] [Related]
6. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Prijovich ZM; Chen KC; Roffler SR
Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
[TBL] [Abstract][Full Text] [Related]
7. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E
Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637
[TBL] [Abstract][Full Text] [Related]
8. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
Yano H; Kayukawa S; Iida S; Nakagawa C; Oguri T; Sanda T; Ding J; Mori F; Ito A; Ri M; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Inagaki H; Suzuki A; Ueda R
Cancer Sci; 2008 Nov; 99(11):2309-14. PubMed ID: 18771527
[TBL] [Abstract][Full Text] [Related]
10. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
11. CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression.
Sato K; Kitajima Y; Kohya N; Koga Y; Ohtaka K; Miyazaki K
Anticancer Res; 2007; 27(2):865-72. PubMed ID: 17465213
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
15. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Ogasawara H; Nishio K; Kanzawa F; Lee YS; Funayama Y; Ohira T; Kuraishi Y; Isogai Y; Saijo N
Jpn J Cancer Res; 1995 Jan; 86(1):124-9. PubMed ID: 7737904
[TBL] [Abstract][Full Text] [Related]
16. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Kojima A; Hackett NR; Ohwada A; Crystal RG
J Clin Invest; 1998 Apr; 101(8):1789-96. PubMed ID: 9541511
[TBL] [Abstract][Full Text] [Related]
17. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
18. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Xu G; Zhang W; Ma MK; McLeod HL
Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S
Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387
[TBL] [Abstract][Full Text] [Related]
20. The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours.
Tobin PJ; Dodds HM; Clarke S; Schnitzler M; Rivory LP
Oncol Rep; 2003; 10(6):1977-9. PubMed ID: 14534729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]